Phase I study of N-methylformamide in patients with advanced cancer

D. S. Ettinger, D. W. Orr, A. P. Rice, R. C. Donehower

Research output: Contribution to journalArticlepeer-review

Abstract

N-Methylformamide (N-MF) belongs to a class of polar-planar compounds which induce cellular differentiation. Preclinical antitumor activity was demonstrated against human mammary, colon, and lung tumor xenografts and L1210 and P388 murine leukemias. This phase I study used a single bolus infusion of N-MF given weekly x 3 doses every 6 weeks. Thirty-five patients were treated with N-MF at doses which ranged from 125 to 3125 mg/m2/week. The dose-limiting toxic effects included nausea and vomiting, anorexia, malaise, and liver function abnormalities. No myelosuppression was seen. The recommended dose for phase II trials of N-MF with this schedule is to initiate therapy at 2000 mg/m2 weekly x 3 and escalate to 2500 mg/m2 if the initial dose was well tolerated.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalCancer Treatment Reports
Volume69
Issue number5
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of N-methylformamide in patients with advanced cancer'. Together they form a unique fingerprint.

Cite this